Patents by Inventor Julia Vaynberg

Julia Vaynberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for treating ILK-mediated diseases
    Patent number: 12116350
    Abstract: The present invention relates to compounds that are modulators of Integrin Linked Kinase (ILK), and methods of treating diseases with such compounds. In certain embodiments, the compounds are within Formulas I-VII (e.g., Csbl-1). In some embodiments, the compounds are used to treat an ILK-mediated disease, such as cancer (e.g., triple negative breast cancer) or an inflammatory disease.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: October 15, 2024
    Assignee: The Cleveland Clinic Foundation
    Inventors: Jun Qin, Koichi Fukuda, Julia Vaynberg, Suguna Rachakonda
  • COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES
    Publication number: 20230127636
    Abstract: The present invention relates to compounds that are modulators of Integrin Linked Kinase (ILK), and methods of treating diseases with such compounds. In certain embodiments, the compounds are within Formulas I-VII (e.g., Csbl-1). In some embodiments, the compounds are used to treat an ILK-mediated disease, such as cancer (e.g., triple negative breast cancer) or an inflammatory disease.
    Type: Application
    Filed: November 1, 2022
    Publication date: April 27, 2023
    Inventors: Jun Qin, Koichi Fukuda, Julia Vaynberg, Suguna Rachakonda
  • Compounds for treating ILK-mediated diseases
    Patent number: 11524945
    Abstract: The present invention relates to compounds that are modulators of Integrin Linked Kinase (ILK), and methods of treating diseases with such compounds. In certain embodiments, the compounds are within Formulas I-VII (e.g., Csbl-1). In some embodiments, the compounds are used to treat an ILK-mediated disease, such as cancer (e.g., triple negative breast cancer) or an inflammatory disease.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: December 13, 2022
    Assignee: The Cleveland Clinic Foundation
    Inventors: Jun Qin, Koichi Fukuda, Julia Vaynberg, Suguna Rachakonda
  • COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES
    Publication number: 20210114993
    Abstract: The present invention relates to compounds that are modulators of Integrin Linked Kinase (ILK), and methods of treating diseases with such compounds. In certain embodiments, the compounds are within Formulas I-VII (e.g., Csbl-1). In some embodiments, the compounds are used to treat an ILK-mediated disease, such as cancer (e.g., triple negative breast cancer) or an inflammatory disease.
    Type: Application
    Filed: January 22, 2019
    Publication date: April 22, 2021
    Inventors: Jun Qin, Koichi Fukuda, Julia Vaynberg, Suguna Rachakonda